metformin vs glp 1 Comparing Glucagon‐like peptide‐1 receptor agonists versus in drug‐naive patients: A nationwide cohort study - Sørensen - 2024 - Journal of Diabetes glp-1 weight management frisco Semaglutide
Description
Recent shortages have frustrated patients, proving that logistics are as critical as innovation
The primary endpoint was major adverse cardiovascular events (often called MACE), a combined measure of: Cardiovascular death Nonfatal heart attack Nonfatal stroke Over a median follow-up of about 3.5 years, semaglutide reduced the relative risk of these events by about 20% compared with placebo
Ozempic is legal but requires a prescription
That creates uncertainty for patients who may begin treatments that many experts view as lifelong therapies
Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B
standard deviation [SD], 3.5 years
